JMP Securities Maintains Market Outperform on Mirum Pharmaceuticals, Lowers Price Target to $66
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on Mirum Pharmaceuticals (MIRM) but lowers the price target from $72 to $66.

May 09, 2024 | 6:39 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JMP Securities maintains a Market Outperform rating on Mirum Pharmaceuticals but lowers the price target from $72 to $66.
While the reduction in price target could suggest a tempered outlook on Mirum Pharmaceuticals' stock performance, the maintenance of a Market Outperform rating indicates continued analyst confidence in the company's fundamentals. This mixed signal could lead to neutral short-term price movement as investors digest the implications of a lower price target against a backdrop of sustained analyst support.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100